Repligen Reports Phase 2b Results for RG2417

Repligen reports disappointing Phase2b results for the use of RG2417 to treat bipolar disorders. RG2417, an oral formulation of uridine, may instead hold promise for ALS as uridine has been shown to improve bioenergetics and confer neuroprotection in ALS mice.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail